In this study, we evaluate the analgesic effect of strontium-89 (Sr-89) for patients with breast cancer having multiple bone metastases and identify positive predictive factors. We retrospectively evaluated 15 patients who were administered Sr-89 for painful bone metastases from breast cancer at St. Marianna University Hospital between January 2010 and April 2014. For patients receiving multiple doses, only the first dose was evaluated. Pain relief was defined as a decrease in the score of the Numeric Rating Scale (NRS) or requirement of reduced doses of pain medication 1 -2 months after being on Sr-89 administration. The associations between pain relief owing to Sr-89 and that owing to bone scan index, interval from bone metastasis onset to Sr-89 administration, zoledronate and denosumab treatment history, hormone therapy/aromatase inhibitor history, and chemotherapy history were assessed. A logistic model was used for statistical analysis. Pain relief was observed in 11 (73.3%) of 15 patients. No statistically significant value was observed between pain relief and bone scan index, interval from bone metastasis onset to Sr-89 administration, zoledronate and denosumab treatment history, hormone therapy/aromatase inhibitor history, and chemotherapy. Thus, Sr-89 was effective for 70% of patients with breast cancer bone metastases, although positive predictive factors for pain relief could not be determined.
mone-dependent cancers such as breast and prostate cancers. Drug therapy with nonsteroidal antiinflammatory drugs (NSAIDs) and narcotics is often used to relieve pain. Zoledronic acid and denosumab are often concomitantly used for delaying the onset of skeletal complications such as increased pain, pathologic fractures, and spinal cord compression. Because external beam radiation provides relief from bone metastasis-induced pain, it is frequently selected for cases in which pain relief from drug therapy is insufficient. External beam radiation is often challenging in cases of multiple bone metastases because the treatment is localized. In November 2007, the use of strontium-89 (Sr-89) as an unsealed source therapy for relief of painful bone metastases was approved in Japan. When Sr-89 is intravenously administered, it is taken up by all sites of abnormal bone turnover. Thus, unlike external beam radiation, a single intravenous dose results in irradiation of multiple bone metastases throughout the skeleton.
However, in breast cancer with bone metastasis, the pain relief rate and predictive factors remain unknown. Therefore, we aimed to evaluate the analgesic effect of Sr-89 in patients with bone metastases from breast cancer and assess the presence of any pain relief predictive factors.
Patients and Methods

Patients
We reviewed the radiological information system and medical history charts of 
Evaluation of the Analgesic Effect of Sr-89
Patients exhibiting improvement according to the Numeric Rating Scale (NRS) or reduced dosage or reduced frequency of painkiller use (NSAIDs, narcotics) 1 -2 months after being on Sr-89 administration were defined as those experiencing analgesia.
Bone Scan Index
Before Sr-89 administration, bone scintigraphy was necessary. Approximately 
Duration from Bone Metastasis Diagnosis Onset until Sr-89 Administration
The median duration from bone metastasis onset until Sr-89 administration was 13 (0 -51) months.
Zoledronate and Denosumab
At the time of Sr-89 administration, zoledronate was being used concomitantly by 10 patients and denosumab by 4.
Hormonal Agents
2 patients were receiving progesterone, 6 were being treated with aromatase inhibitors, and 1 was receiving exemestane.
Chemotherapeutic Agents
Chemotherapeutic agents were used concomitantly for 8 patients (S-1 for 1 patient, capecitabine for 1, doxifluridine + cyclophosphamide for 1, docetaxel + trastuzumab for 1, trastuzumab for 3, trastuzumab + pertuzumab for 1).
Adverse Events
Adverse events owing to Sr-89 were evaluated using the National Cancer Institute's Common Terminology Criteria (CTCAE V3.0). 
Statistical Analysis
We used a logistic model to assess pain relief. The significance level was set as ≤5%. Statistical processing was performed using the R software.
Results
The patient's characteristics are given in Table 1 .
Analgesia
Significant analgesia was observed in 11 (73.7%) of 15 patients. The dosage of painkillers (including the frequency of rescue) was observed in 5 patients (33.3%), and improvement in NRS was observed in 6 patients (40.0%).
BSI
The relationship between BSI and pain relief owing to Sr-89 was not statically significant (odds ratio: 0.869, 95% CI: 0.695 -1.150, p = 0.322).
Duration from Bone Metastasis Diagnosis Onset until Sr-89 Administration
In 
Zoledronate and Denosumab
In 10 patients, zoledronic acid and Sr-89 was used in combination and significant analgesia was observed in 6 (60.0%) patients. In 4 patients, denosumab and Sr-89 was used in combination and significant analgesia was observed in 4 (100.0%) patients. The relationship between zoledronic acid or denosumab and pain relief owing to Sr-89 was not statically significant (odds ratio: 1.330, 95% CI: 0.089 -20.70, p = 0.837).
Hormonal Agents
In 9 patients, hormonal agents and Sr-89 was used in combination and significant analgesia was observed in 7 (77.8%) patients. In 6 patients, hormonal agents and Sr-89 was not used in combination and significant analgesia was observed in 4 (66.7%) patients. The relationship between hormonal agents and pain relief owing to Sr-89 was not statically significant (odds ratio: 1.750, 95% CI: 0.173 -17.70, p = 0.635).
Chemotherapeutic Agents
In 8 patients, chemotherapeutic agents and Sr-89 was used in combination and significant analgesia was observed in 5 (62.5%) patients. In 7 patients, chemotherapeutic agents and Sr-89 was not used in combination and significant analgesia was observed in 6 (75.0%) patients. The relationship between chemotherapy and pain relief owing to Sr-89 was not statically significant (odds ratio: 0.278, 95% CI: 0.021 -3.58, p = 0.326).
Discussion
In this study, we found that Sr-89 improve the bone metastatic pain in 70% patients with breast cancer bone metastases, although we were unable to determine positive predictive factors for pain relief.
For breast cancer patients with bone metastases who do not achieve enough pain relief from pain medication, external beam radiation is frequently selected.
However, a limitation of external beam radiation is its purely local effect, rendering it ineffective if there are multiple indistinct painful sites. After pain at the most intense site is improved by external beam radiation, pain is then frequently experienced at other locations, requiring multiple external beam treatments. External beam therapy is contraindicated when interstitial pneumonia is present in the radiation field [1] . In the vertebral body, once radiation has been performed, the amount of radiation to the spine is limited by the total dose to the spinal cord. In some cases, re radiation to the spine is reported [2] . But, the safety of re tended to be diminished in osteolytic bone sites [5] .
Kraeber reported that in 94 cases of prostate cancer metastasis to the bone, pain relief owing to Sr-89 was observed at about the same rate in cases with 10 or fewer metastases and cases with widespread bone metastases (77%, 75%), but a significant difference (P = 0.005) was observed in the rates of complete disappearance of pain in cases with 10 or fewer metastases (54%) and widespread bone metastases (24%) [6] . The reason for this may be that if the skeletal tumor burden is small, the accumulation of Sr-89 in each focus is higher and the pain improvement effect is greater than that in widespread bone metastases with the same amount of Sr-89 distributed over a large tumor burden. However, in our study, the relationship between BSI and pain relief owing to Sr-89 was not statically significant. We did not evaluate the rate of complete disappearance of pain as sample size is small and this study is retrospective study. However, although there are differences between prostate cancer and breast cancer, we cannot state that bone metastasis tumor burden is involved in the effects of Sr-89 on pain. Windsor ported that when zoledronate and Sr-89 were used simultaneously, the pain improvement effect was superior than when zoledronate or Sr-89 was used alone [12] , suggesting an additive or synergistic effect. There are no reports on the concomitant use of denosumab and Sr-89. However, no significant difference was observed between Sr-89 with zoledronate acid and Sr-89 with denosumab.
In our study, Sr-89 was effective in 70% of cases; however, positive predictive factors for pain relief could not be determined. In addition, external beam radiation, BSI, and duration from bone metastasis diagnosis onset until Sr-89 administration were not predictive factors for pain relief.
This study had limitations. First, the sample size of the study was small.
Second this study had a retrospective design. Therefore, further accumulation of patients and Ko
Conclusion
In patients with breast cancer bone metastases, Sr-89 is effective in 70% of cases, although positive predictive factors for pain relief remained unknown.
